{
  "Q0": "Whole Exome Sequencing (WES)",
  "Q1": "Yes",
  "Q2": "Yes",
  "Q3": "Yes",
  "Q4": "Yes",
  "Q4-1": "Yes",
  "Q4-2": "ACMG",
  "Q5": "Yes",
  "Q6": "No",
  "Q7": "Yes",
  "Q8": "No",
  "Q9": "Yes",
  "Q9-1": "Yes",
  "Q10": "No",
  "Q10-1": "Diagnostic",
  "Q11": "Yes",
  "Q12": "No",
  "Q13": "Yes",
  "Q14": "Not listed",
  "Q15": "Yes",
  "Q15-1": "Patient has dysmorphic features and family history of intellectual disability in addition to ASD features",
  "Q16": "No",
  "Q17": "The policy refers to a separate 'Exome Sequencing' guideline that would need to be consulted for specific coverage criteria for WES. The current policy document indicates that comprehensive panels for ASD/ID/GDD are not covered, but separate guidelines may apply for patients with additional findings beyond ASD/ID/GDD. Pre-authorization would be required, and documentation should emphasize the dysmorphic features, family history, and completion of first-tier testing.",
  "match": false
}